Cancer Vaccines
BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
Published in Gene Therapy Weekly, June 19th, 2008
A Phase I/II safety and tolerability study in 18 male patients with non-metastatic as well as hormone-insensitive prostate cancer has begun enrolment in the US. Secondary objectives of the trial include examining the ability of the vaccine to induce prostate antigen-specific immune responses, as well as clinical anti-tumor activity. Preliminary data is expected during second half year 2009.
The therapeutic vaccine, based on the company's MVA-BN(R) technology, is designed to generate cellular and humoral immune...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2008-06-19)
More Articles from Gene Therapy Weekly
- Cold Spring Harbor Laboratory
CSHL scientists trace causal link between a tumor suppressor gene and liver cancer - Acute Pancreatitis
Researchers from State University of New York describe findings in acute pancreatitis - Angiogenesis
New angiogenesis research from G.Y. Zhang and colleagues discussed - Angiogenesis
Researchers at Osaka University publish new data on angiogenesis - BioMarin Pharmaceutical Inc.
BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio a Syndrome - Bladder Cancer
Research from Hokkaido University, Medical Department yields new data on bladder cancer - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
